Search

Your search keyword '"Knoop, Ann"' showing total 429 results

Search Constraints

Start Over You searched for: Author "Knoop, Ann" Remove constraint Author: "Knoop, Ann"
429 results on '"Knoop, Ann"'

Search Results

11. Locoregional Lymph Node Metastasis from Clinically Occult Breast Cancer: Prognostic Significance of Mastectomy.

14. Incidence and survival of primary metastatic breast cancer in Denmark:implication of breast cancer screening, classification, and staging practice

15. Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study

16. Development and Methodological Validation of a Modified Staging System for de Novo Metastatic Breast Cancer

22. Prediction of fulvestrant efficacy in patients with advanced breast cancer: retrospective-prospective evaluation of the predictive potential of a multigene expression assay

24. Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study

33. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark

34. A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients

35. Adjuvant treatment with trastuzumab of patients with HER2-positive, T1a-bN0M0 breast tumors:A systematic review and meta-analysis

36. Identifying recurrent breast cancer patients in national health registries using machine learning

37. Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer:a nationwide study

38. Real-world survival of Danish patients with HER2-positive metastatic breast cancer

39. A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark

41. Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer.

43. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study

47. Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm:a nationwide study

48. First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3):Population-Based Real-World Data From the DBCG

49. Inter-observer agreement of tumor infiltrating lymphocytes in primary HER2-positive breast cancer and correlation between tissue microarray and full tumor-sections

50. sj-docx-1-bcb-10.1177_11782234221086992 ��� Supplemental material for First-Line Treatment of HER2-Positive Metastatic Breast Cancer With Dual Blockade Including Biosimilar Trastuzumab (SB3): Population-Based Real-World Data From the DBCG

Catalog

Books, media, physical & digital resources